Progyny, Inc.

Progyny, Inc. Announces Third Quarter 2026 Results

Progyny reported record Q3 2026 revenue of $341.3 million, up 8.9% YoY, with net income of $26.3 million ($0.32 diluted EPS) nearly double the prior year's $13.9 million ($0.15). Gross margin expanded to 24.5% from 23.2%, and Adjusted EBITDA rose 6.3% to $58.4 million. The recent selling season delivered a record 1.3 million new covered lives and over 85 new clients, with near-100% retention into 2027. Management raised the midpoint of full-year guidance: FY26 revenue of $1.365B-$1.385B and Adjusted EBITDA of $235M-$240M. The company repurchased $82.7 million of stock in Q3 and holds $195.6 million in cash with no debt.

•4d ago

New Progyny Study Finds Significant Improvement in Menopause Symptoms Through Connected Care Model

Progyny published clinical outcomes showing 70.8% of members in its Menopause and Midlife program experienced overall symptom improvement, with an average 7.1-point gain on the Menopause Rating Scale. Members receiving both coaching and care from menopause-trained providers improved 7.6 points versus 3.3 points for coaching alone, supporting the company's connected-care model as a differentiator. The retrospective study of 179 members does not establish causation, and no financial impact was disclosed, but the findings bolster the marketing case for Progyny's expanding employer benefits offering.

•13d ago

Progyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting

Progyny will present real-world outcomes research from its employer-sponsored Menopause and Midlife program at The Menopause Society 2026 Annual Meeting in San Diego, October 20-24. The study, conducted in partnership with Morehouse School of Medicine, evaluated access, engagement, and symptom improvement among women in the program, and will be presented by Dr. Gloria Richard-Davis on October 22. The announcement is a visibility/credibility event supporting Progyny's expansion beyond fertility into the broader women's health continuum, but contains no financial or clinical-catalyst data.

•24d ago

Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics

Progyny says its annual selling season is pacing to a potential record level of new lives added to its managed fertility solution. Based on commitments received to date plus anticipated remaining decisions, the company expects 1.2 million new covered lives from client launches throughout the first half of 2027. CEO Pete Anevski attributes the momentum to record expected increases in overall medical plan costs in 2027, arguing employers are turning to Progyny's cost-management and clinical-outcomes track record.

•1mo ago

Progyny, Inc. Announces Second Quarter 2026 Results

Progyny reported Q2 revenue of $350.5 million, up 5.3% year-over-year, with GAAP EPS doubling to $0.34 driven by gross margin expansion to 25.5%. Excluding a lapsed large client, organic revenue growth accelerated to 11.0%, reflecting strong member engagement and increased client adoption. The company provided full-year 2026 revenue guidance of $1.36 billion to $1.385 billion, representing growth of 5.5% to 7.5%, or 9.7% to 11.7% on an organic basis excluding the prior-year client. Balance sheet strength remained evident with $236.9 million in cash and no debt, as the company repurchased 1.2 million shares for $31.5 million during the quarter.

•3mo ago

Progyny, Inc. Announces Share Repurchase Program

Progyny's Board of Directors has authorized a new share repurchase program for up to $200 million of its common stock. The company stated the program will be funded through available cash balances, indicating strong liquidity. Repurchases may occur via open market transactions or Rule 10b5-1 plans, subject to market conditions and at the company's discretion.

•5mo ago

Progyny, Inc. Announces First Quarter 2026 Results

Progyny reported Q1 revenue of $328.5 million, up 1.4% year-over-year, and net income of $24.2 million, or $0.29 per diluted share, significantly topping the prior year's $0.17. Gross margin expanded to 25.3% from 23.4% in the prior year, driven by operational efficiencies and lower stock-based compensation, while the company fully utilized its $200 million share repurchase authorization by buying back 8.8 million shares since November. The company raised its full-year 2026 revenue guidance to $1.365 billion to $1.405 billion, representing 5.9% to 9.0% growth, or 10.1% to 13.3% excluding a large client lost in 2025.

•6mo ago